Aethlon Medical, Inc. (AEMD) Bundle
A Brief History of Aethlon Medical, Inc. (AEMD)
Company Overview
Aethlon Medical, Inc. is a medical device company headquartered in San Diego, California. The company focuses on developing therapeutic technologies to address unmet medical needs.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Stock Price Range |
|---|---|---|---|
| 2023 | $2.1 million | ($14.3 million) | $0.20 - $0.80 |
Key Product: Hemopurifier
The company's primary technological platform is the Hemopurifier, designed to remove harmful viruses and cancer-promoting exosomes from the bloodstream.
Research and Development Focus
- COVID-19 therapeutic interventions
- Cancer exosome removal
- Infectious disease treatment
Nasdaq Listing Details
Ticker Symbol: AEMD
Market Capitalization: Approximately $30 million as of January 2024
Clinical Trials and Research
| Research Area | Current Status | Funding |
|---|---|---|
| COVID-19 Treatment | Ongoing clinical evaluation | $1.5 million grant support |
| Cancer Exosome Removal | Pre-clinical stage | $750,000 research funding |
Shareholder Information
Outstanding Shares: 45.2 million
Institutional Ownership: 12.4%
Recent Corporate Developments
- Continued focus on Hemopurifier technology
- Ongoing clinical research partnerships
- Cost management strategies
Who Owns Aethlon Medical, Inc. (AEMD)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 1,028,915 | 3.82% |
| BlackRock Inc | 724,993 | 2.69% |
| Renaissance Technologies LLC | 402,725 | 1.49% |
Insider Ownership
- James A. Joyce - Chairman/CEO: 2,214,464 shares
- Nicholas Rigazio - Chief Financial Officer: 47,500 shares
- Charles J. Fisher Jr. - Chief Medical Officer: 35,000 shares
Ownership Structure
Aethlon Medical, Inc. is a publicly traded company listed on the NASDAQ under the ticker symbol AEMD. Total outstanding shares: 26,957,662.
Institutional Ownership Percentage
Total institutional ownership: 15.37% as of most recent filing.
Aethlon Medical, Inc. (AEMD) Mission Statement
Company Overview
Aethlon Medical, Inc. is a medical device company focused on developing innovative therapeutic technologies to address unmet medical needs.
Key Technology Focus
- Hemopurification platform technology
- Exosome technology for cancer and infectious disease treatment
- Development of Aethlon Hemopurifier devices
Financial Performance
| Fiscal Year | Total Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $1.42 million | ($14.3 million) | $5.1 million |
Research and Development Focus
- COVID-19 therapeutic interventions
- Cancer exosome research
- Immunotherapy platforms
Stock Information
| Trading Symbol | Exchange | Stock Price (as of January 2024) | Market Capitalization |
|---|---|---|---|
| AEMD | NASDAQ | $0.38 | $23.5 million |
Strategic Objectives
Primary mission: Develop advanced therapeutic technologies to address complex medical challenges through innovative hemopurification and exosome platforms.
How Aethlon Medical, Inc. (AEMD) Works
Company Overview
Aethlon Medical, Inc. is a medical device company focused on developing technologies to address unmet medical needs.
Key Technology Platform
The company specializes in the Hemopurifier technology, a therapeutic device designed to combat various viral and cancer-related conditions.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $2.1 million |
| Net Loss | $14.3 million |
| Cash and Cash Equivalents | $6.5 million |
Research Focus Areas
- Viral Immunotherapy
- Cancer Treatment
- Exosome Research
Product Development
Current primary research targets include:
- COVID-19 treatment applications
- Cancer exosome elimination
- Immunocompromised patient therapies
Stock Information
| Stock Detail | Current Value |
|---|---|
| Ticker Symbol | AEMD |
| Stock Price (January 2024) | $0.23 |
| Market Capitalization | $25.6 million |
Research and Development Expenditure
R&D spending in 2023: $9.2 million
Intellectual Property
- Multiple U.S. and international patents
- Proprietary Hemopurifier technology
How Aethlon Medical, Inc. (AEMD) Makes Money
Revenue Streams
Aethlon Medical, Inc. generates revenue through the following primary sources:
- Medical device development
- Research and development contracts
- Grant funding
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $2.1 million |
| Net Loss | $14.3 million |
| Cash and Cash Equivalents | $5.6 million |
Key Product Revenue
Aethlon Medical focuses on developing the Aethlon Hemopurifier, a medical device targeting infectious diseases and cancer.
- Hemopurifier research contracts: $1.2 million
- Grant income: $900,000
- Collaborative research agreements: $350,000
Research Funding Sources
| Funding Source | Amount |
|---|---|
| National Institutes of Health (NIH) | $650,000 |
| Department of Defense | $450,000 |
Stock Performance
NASDAQ ticker AEMD trading range in 2023: $0.30 - $1.20 per share
Operating Expenses
- Research and development: $10.5 million
- General and administrative: $3.8 million
Aethlon Medical, Inc. (AEMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.